Among patients with hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer, the increase in proportion of patients receiving adjuvant chemotherapy and endocrine therapy (ET) increased simultaneously [[8], [9], [10]]. Here, ERBB2 is linked to breast carcinoma.